Novartis strikes $3 billion deal for experimental cancer therapy
FRANKFURT, Germany: Novartis has agreed to acquire an experimental breast cancer drug from U.S.-based Synnovation Therapeutics in a…
Novartis Bolsters Oncology Pipeline with Multi-Billion Dollar Acquisition
Novartis bets up to $3B on Pikavation’s SNV4818, a drug candidate aimed at reducing side effects in breast…
Novartis Bolsters Cancer Portfolio with Major $3 Billion Acquisition
Novartis, Bolsters
21.03.2026 – 05:57:11 | boerse-global.de
Novartis acquires PI3K-alpha inhibitor SNV4818 in a…
Novartis Expands Cancer Drug Portfolio with $3 Billion Acquisition
In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement…
Novartis’ Bold Move: Acquiring Potential Game-Changer in Breast Cancer Treatment
In a significant move within the pharmaceutical sector, Novartis has struck a deal to acquire SNV4818, a…